Dr. Edgardo Santos' Interview with Daniel Petrylak, MD
Update: 2025-08-25
Description
Interviews with Summit Director Edgardo S. Santos Castillero, MD, FACP, FASCO
NOSCM 2024 | New Orleans SummerCancer Meeting
Dr. Edgardo Santos' Interview with Daniel Petrylak, MD
Dr. Petrylak, an international expert on prostate cancer, noted that microsatellite instability occurs in roughly 2% of prostate cancers—making those patients pembrolizumab‐eligible—and championed the use of doublet or triplet regimens in de novo metastatic, hormone‐sensitive disease to markedly improve overall survival. For castration‐resistant disease, he recommended routine DNA repair mutation profiling and PSMA PET imaging—from high-risk localized cases to asymptomatic relapse—and to guide lutetium-177 PSMA therapy.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
